As­traZeneca and Dai­ichi Sankyo con­tin­ue to flesh out En­her­tu plans, claim­ing win in ear­li­er breast can­cer line

As­traZeneca and Dai­ichi Sankyo have big plans for their block­buster-in-the-mak­ing En­her­tu, and the pair tout­ed an­oth­er win Mon­day morn­ing in the quest to con­quer the breast can­cer mar­ket.

En­her­tu reached its pri­ma­ry end­point in a study look­ing at HER2-pos­i­tive metasta­t­ic breast can­cer pa­tients who had pre­vi­ous­ly been treat­ed with one pri­or line of HER2-based ther­a­py, the com­pa­nies an­nounced, demon­strat­ing su­pe­ri­or­i­ty in pro­gres­sion-free sur­vival over Roche’s Kad­cy­la and chemo. Full da­ta aren’t avail­able yet, but Dai­ichi Sankyo not­ed the tri­al has been rec­om­mend­ed for un­blind­ing by the IMDC af­ter reach­ing this in­ter­im analy­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER